Literature DB >> 16011451

A review of clozapine safety.

Joanna Fitzsimons1, Michael Berk, Timothy Lambert, Michel Bourin, Seetal Dodd.   

Abstract

Clozapine is a distinctive antipsychotic agent, having a unique clinical profile and an idiosyncratic safety profile. More so than with other agents, the weighting of its adverse event profile is critical, in order to counterbalance its clear clinical advantages. The safety issues with clozapine are in a number of areas, some of which are considered medical emergencies and potentially life-threatening. These include haematological (neutropenia and agranulocytosis), CNS (seizures), cardiovascular (myocarditis and cardiomyopathy), metabolic (diabetes), gastrointestinal and neuromuscular. Understanding the safety profile of clozapine allows an informed use of the agent that can maximise its clear clinical benefit and minimise the known risks.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16011451     DOI: 10.1517/14740338.4.4.731

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  12 in total

Review 1.  [Pharmacotherapy for schizophrenia].

Authors:  W W Fleischhacker; W Hummer
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

Review 2.  Continuing clozapine treatment with lithium in schizophrenic patients with neutropenia or leukopenia: brief review of literature with case reports.

Authors:  Memduha Aydin; Bilge Cetin Ilhan; Saliha Calisir; Seda Yildirim; Ibrahim Eren
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

Review 3.  Cardiovascular Disease in Clozapine-Treated Patients: Evidence, Mechanisms and Management.

Authors:  Kathlyn J Ronaldson
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

4.  Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics.

Authors:  Heidrun Appl; Tobias Holzammer; Stefan Dove; Ekkehard Haen; Andrea Strasser; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-28       Impact factor: 3.000

Review 5.  Seizure associated with clozapine: incidence, etiology, and management.

Authors:  Andrew M Williams; Susie H Park
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

6.  Relegating Psychosis: Blood Work and "Routine Connection" in the Clozapine Clinic.

Authors:  Julia E H Brown
Journal:  Cult Med Psychiatry       Date:  2020-06

7.  [Evidence-based treatment of psychosis associated with Parkinson's disease].

Authors:  R Haussmann; M Bauer; M Donix
Journal:  Nervenarzt       Date:  2016-05       Impact factor: 1.214

8.  Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis.

Authors:  Marlene Bloechliger; Stephan Rüegg; Susan S Jick; Christoph R Meier; Michael Bodmer
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

9.  Life-threatening haematemesis associated with clozapine: a case report and literature review.

Authors:  Kazeem Olaide Adebayo; Nurudeen Ibrahim; Temilola Mosanya; Benjamin Eegunranti; Babatunde Suleiman; Akeem Ayankunle
Journal:  Ther Adv Psychopharmacol       Date:  2013-10

10.  Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up.

Authors:  Heidi Taipale; Juha Mehtälä; Antti Tanskanen; Jari Tiihonen
Journal:  Schizophr Bull       Date:  2018-10-17       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.